Anixa Biosciences is trading 15.27% down now at $3.05 after falling sharply before the August 28, 2026 open; no confirmed company-specific announcement, filing, earnings release, or clinical update has been identified to explain the decline.
- The company’s latest listed release concerned a September investor conference presentation, rather than a new operating or clinical catalyst.
- The move appears disconnected from the provided broader market backdrop, leaving the cause unclear.